Hemostatic Radiotherapy and Multidisciplinary Management for Bleeding Gastric Cancer

Gastrointestinal cancers frequently present with severe symptoms such as bleeding, pain, and obstruction—factors that substantially impair quality of life and prognosis. Hemostatic and palliative radiotherapy offers a rapid, effective, and minimally invasive means of achieving symptom control, particularly when surgery, endoscopic intervention, or embolization is not feasible. Despite its broad clinical utility, several major evidence gaps remain regarding optimal dose-fractionation, patient selection, predictors of response, and global variations in practice.Advances in imaging biomarkers—such as MRI diffusion metrics (ADC), dual-energy CT iodine mapping, and radiomics—provide exciting opportunities for early response prediction and personalized treatment selection. However, their integration into routine clinical management is still limited.Hemostatic radiotherapy remains one of the most impactful interventions in advanced gastrointestinal cancers, especially when rapid control of malignant bleeding is required. Yet, evidence is scattered, dose-fractionation is inconsistent, and predictive tools are immature.This Research Topic aims to consolidate clinical, translational, and real-world evidence to define best practices in hemostatic and palliative radiotherapy for gastrointestinal cancers. By assembling an international editorial team representing Asia, North America, and Europe, this Topic will bridge global perspectives, unify fragmented evidence, and help shape future practice guidelines. Our ultimate goal is to advance precision palliation and improve patient-centered outcomes in advanced GI oncology.We welcome submissions that address, but are not limited to, the following themes:Clinical Researcho Hemostatic radiotherapy for gastric and gastrointestinal bleedingo Short-course radiotherapy regimens (e.g., 8 Gy × 1, 20 Gy in 5 fractions, Quad Shot)o Use of IMRT/SBRT and re-irradiation in palliative and hemostatic settingsBiomarkers and Imagingo Use of MRI diffusion metrics (ADC), dual-energy CT (DECT), iodine mapping, and radiomics in hemostatic and palliative radiotherapyo Imaging and circulating biomarkers for early response prediction and treatment adaptationMultidisciplinary Care and Systemic Therapy Integrationo Multidisciplinary pathways involving radiation oncology, gastroenterology/endoscopy, medical oncology, interventional radiology, surgery, and palliative careo Integration of hemostatic and palliative radiotherapy with modern systemic therapies (e.g., chemotherapy, targeted agents, immunotherapy)Real-World Evidence and Practice Patternso Multicenter or registry-based real-world datasets on hemostatic and palliative radiotherapy for gastrointestinal cancerso Regional and institutional practice variations in indications, dose-fractionation, techniques, and supportive careo Health services research, resource utilization, and cost-effectiveness analysesPlease note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal. Topic editors: Osamu Tanaka, Cornelis F.M. Sier Source: https://www.frontiersin.org/research-topics/76513/hemostatic-radiotherapy-and-multidisciplinary-management-for-bleeding-gastric-cancer